Erasca (ERAS) to Release Earnings on Wednesday

Erasca (NASDAQ:ERAS) is projected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 14th. Analysts expect Erasca to post earnings of ($0.12) per share for the quarter.

Erasca (NASDAQ:ERAS) last announced its earnings results on Thursday, March 20th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. During the same quarter in the prior year, the business posted ($0.20) earnings per share. On average, analysts expect Erasca to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Erasca Stock Performance

ERAS stock opened at $1.39 on Tuesday. Erasca has a 52 week low of $1.01 and a 52 week high of $3.45. The company has a market capitalization of $393.77 million, a price-to-earnings ratio of -1.67 and a beta of 1.12. The firm’s 50-day moving average is $1.35 and its two-hundred day moving average is $1.98.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ERAS shares. Raymond James started coverage on Erasca in a report on Wednesday, March 26th. They issued an “outperform” rating and a $5.00 price objective for the company. The Goldman Sachs Group lowered their target price on Erasca from $3.50 to $3.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Morgan Stanley reaffirmed an “overweight” rating and set a $4.00 price target on shares of Erasca in a research note on Friday, March 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Erasca in a research note on Wednesday, April 30th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $4.83.

Erasca Company Profile

Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.